Cargando…
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the young population. Few options of systemic treatment are available once they become unresectable and resistant to conventional chemotherapy. A better knowledge of the key role that tyrosine kinase receptors (VEGFR, RET,...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697271/ https://www.ncbi.nlm.nih.gov/pubmed/36430263 http://dx.doi.org/10.3390/ijms232213784 |
_version_ | 1784838519978459136 |
---|---|
author | Albarrán, Víctor Villamayor, María Luisa Chamorro, Jesús Rosero, Diana Isabel Pozas, Javier San Román, María Calvo, Juan Carlos Pérez de Aguado, Patricia Moreno, Jaime Guerrero, Patricia González, Carlos García de Quevedo, Coral Álvarez-Ballesteros, Pablo Vaz, María Ángeles |
author_facet | Albarrán, Víctor Villamayor, María Luisa Chamorro, Jesús Rosero, Diana Isabel Pozas, Javier San Román, María Calvo, Juan Carlos Pérez de Aguado, Patricia Moreno, Jaime Guerrero, Patricia González, Carlos García de Quevedo, Coral Álvarez-Ballesteros, Pablo Vaz, María Ángeles |
author_sort | Albarrán, Víctor |
collection | PubMed |
description | Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the young population. Few options of systemic treatment are available once they become unresectable and resistant to conventional chemotherapy. A better knowledge of the key role that tyrosine kinase receptors (VEGFR, RET, MET, AXL, PDGFR, KIT, FGFR, IGF-1R) may play in the pathogenesis of these tumors has led to the development of multi-target inhibitors (TKIs) that are progressively being incorporated into our therapeutic arsenal. Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical trials (cabozantinib, regorafenib, apatinib, sorafenib, and lenvatinib). Although the development of TKIs for other primary bone tumors is less advanced, preclinical data and early trials have begun to show their potential benefit in advanced Ewing sarcoma (ES) and rarer bone tumors (chondrosarcoma, chordoma, giant cell tumor of bone, and undifferentiated pleomorphic sarcoma). Previous reviews have mainly provided information on TKIs for OS and ES. We aim to summarize the existing knowledge regarding the use of TKIs in all bone sarcomas including the most recent studies as well as the potential synergistic effects of their combination with other systemic therapies. |
format | Online Article Text |
id | pubmed-9697271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96972712022-11-26 Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas Albarrán, Víctor Villamayor, María Luisa Chamorro, Jesús Rosero, Diana Isabel Pozas, Javier San Román, María Calvo, Juan Carlos Pérez de Aguado, Patricia Moreno, Jaime Guerrero, Patricia González, Carlos García de Quevedo, Coral Álvarez-Ballesteros, Pablo Vaz, María Ángeles Int J Mol Sci Review Bone sarcomas are a heterogeneous group of rare tumors with a predominance in the young population. Few options of systemic treatment are available once they become unresectable and resistant to conventional chemotherapy. A better knowledge of the key role that tyrosine kinase receptors (VEGFR, RET, MET, AXL, PDGFR, KIT, FGFR, IGF-1R) may play in the pathogenesis of these tumors has led to the development of multi-target inhibitors (TKIs) that are progressively being incorporated into our therapeutic arsenal. Osteosarcoma (OS) is the most frequent primary bone tumor and several TKIs have demonstrated clinical benefit in phase II clinical trials (cabozantinib, regorafenib, apatinib, sorafenib, and lenvatinib). Although the development of TKIs for other primary bone tumors is less advanced, preclinical data and early trials have begun to show their potential benefit in advanced Ewing sarcoma (ES) and rarer bone tumors (chondrosarcoma, chordoma, giant cell tumor of bone, and undifferentiated pleomorphic sarcoma). Previous reviews have mainly provided information on TKIs for OS and ES. We aim to summarize the existing knowledge regarding the use of TKIs in all bone sarcomas including the most recent studies as well as the potential synergistic effects of their combination with other systemic therapies. MDPI 2022-11-09 /pmc/articles/PMC9697271/ /pubmed/36430263 http://dx.doi.org/10.3390/ijms232213784 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Albarrán, Víctor Villamayor, María Luisa Chamorro, Jesús Rosero, Diana Isabel Pozas, Javier San Román, María Calvo, Juan Carlos Pérez de Aguado, Patricia Moreno, Jaime Guerrero, Patricia González, Carlos García de Quevedo, Coral Álvarez-Ballesteros, Pablo Vaz, María Ángeles Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas |
title | Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas |
title_full | Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas |
title_fullStr | Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas |
title_full_unstemmed | Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas |
title_short | Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas |
title_sort | receptor tyrosine kinase inhibitors for the treatment of recurrent and unresectable bone sarcomas |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697271/ https://www.ncbi.nlm.nih.gov/pubmed/36430263 http://dx.doi.org/10.3390/ijms232213784 |
work_keys_str_mv | AT albarranvictor receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT villamayormarialuisa receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT chamorrojesus receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT roserodianaisabel receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT pozasjavier receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT sanromanmaria receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT calvojuancarlos receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT perezdeaguadopatricia receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT morenojaime receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT guerreropatricia receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT gonzalezcarlos receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT garciadequevedocoral receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT alvarezballesterospablo receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas AT vazmariaangeles receptortyrosinekinaseinhibitorsforthetreatmentofrecurrentandunresectablebonesarcomas |